Paper41728076
Porphyrin-coated gold nanoparticles associated with X-rays and proton therapy in the treatment of triple-negative breast cancer.
Silva CR and 3 others. Nanoscale Adv, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Porphyrin-coated gold nanoparticles associated with X-rays and proton therapy in the treatment of triple-negative breast cancer. Papers, record 41728076. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41728076
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Porphyrin-coated gold nanoparticles associated with X-rays and proton therapy in the treatment of triple-negative breast cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37513983 | Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37513983 | PubMed |
| 2 | 29338744 | New insights in the relative radiobiological effectiveness of proton irradiation. | Radiat Oncol | 2018 | https://conductscience.org/library/papers/29338744 | PubMed |
| 3 | 25602130 | Nanoparticles in photodynamic therapy. | Chem Rev | 2015 | https://conductscience.org/library/papers/25602130 | PubMed |
| 4 | 31650249 | Investigation of combined photodynamic and radiotherapy effects of gallium phthalocyanine chloride on MCF-7 breast cancer cells. | J Biol Inorg Chem | 2020 | https://conductscience.org/library/papers/31650249 | PubMed |
| 5 | 36975432 | The Potential of Proton Therapy for Locally Advanced Breast Cancer: Clinical and Technical Considerations. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36975432 | PubMed |
| 6 | 20121172 | One-phase synthesis of water-soluble gold nanoparticles with control over size and surface functionalities. | Langmuir | 2010 | https://conductscience.org/library/papers/20121172 | PubMed |
| 7 | 36868521 | Proton Beam Therapy for Early Breast Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes. | Int J Radiat Oncol Biol Phys | 2023 | https://conductscience.org/library/papers/36868521 | PubMed |
| 8 | 36623701 | Research progress of potential factors influencing photodynamic therapy for gastrointestinal cancer. | Photodiagnosis Photodyn Ther | 2023 | https://conductscience.org/library/papers/36623701 | PubMed |
| 9 | 34575408 | Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34575408 | PubMed |
| 10 | 36218130 | Photodynamic therapy in breast cancer treatment. | J Appl Biomed | 2022 | https://conductscience.org/library/papers/36218130 | PubMed |
| 11 | 35613354 | Mechanisms and mathematical modeling of ROS production by the mitochondrial electron transport chain. | Am J Physiol Cell Physiol | 2022 | https://conductscience.org/library/papers/35613354 | PubMed |
| 12 | 30427254 | The role of thioredoxin reductase in gold nanoparticle radiosensitization effects. | Nanomedicine (Lond) | 2018 | https://conductscience.org/library/papers/30427254 | PubMed |
| 13 | 39776332 | Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/39776332 | PubMed |
| 14 | 30791480 | Thioredoxin Reductase Activity Predicts Gold Nanoparticle Radiosensitization Effect. | Nanomaterials (Basel) | 2019 | https://conductscience.org/library/papers/30791480 | PubMed |
| 15 | 21082814 | Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. | ACS Nano | 2010 | https://conductscience.org/library/papers/21082814 | PubMed |
| 16 | 29491463 | Target delivery of doxorubicin tethered with PVP stabilized gold nanoparticles for effective treatment of lung cancer. | Sci Rep | 2018 | https://conductscience.org/library/papers/29491463 | PubMed |
| 17 | 21262347 | Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay. | Free Radic Biol Med | 2011 | https://conductscience.org/library/papers/21262347 | PubMed |
| 18 | 27184417 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/27184417 | PubMed |
| 19 | 25361443 | Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. | Phys Med Biol | 2014 | https://conductscience.org/library/papers/25361443 | PubMed |
| 20 | 33262595 | Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy. | Int J Nanomedicine | 2020 | https://conductscience.org/library/papers/33262595 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883253 | Porphyrin-Based Compounds in Medicine: From Photodynamic Therapy to Theranostics. | Molecules | 2026 | https://conductscience.org/library/papers/42883253 | PubMed |
| 42559173 | Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics. | Theranostics | 2026 | https://conductscience.org/library/papers/42559173 | PubMed |
| 42074099 | Application Advances of Gold Nanoparticles in Cancer Theranostics: From Physicochemical Mechanisms to Multifunctional Nanoplatforms. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074099 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PRDX5 | 25824 | PubTator's text mining | https://conductscience.org/library/genes/25824 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41728076
GET https://conductscience.org/api/papers/v1/41728076/references?page=2